Compare UEC & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEC | KLTOW |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | N/A |
| IPO Year | N/A | 2022 |
| Metric | UEC | KLTOW |
|---|---|---|
| Price | $13.02 | $0.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.80 | N/A |
| AVG Volume (30 Days) | ★ 9.2M | N/A |
| Earning Date | 12-10-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,750,000.00 | N/A |
| Revenue This Year | $0.59 | N/A |
| Revenue Next Year | $112.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 189.19 | N/A |
| 52 Week Low | $3.85 | N/A |
| 52 Week High | $17.80 | N/A |
| Indicator | UEC | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 44.16 |
| Support Level | $12.52 | $0.13 |
| Resistance Level | $14.07 | $0.15 |
| Average True Range (ATR) | 0.93 | 0.02 |
| MACD | 0.18 | 0.00 |
| Stochastic Oscillator | 56.32 | 11.61 |
Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.